Wyeth (Collegeville, Pa) recently announced FDA approval for Protonix I.V. (pantoprazole sodium) for Injection, for intravenous administration over a period of at least 2 minutes, in addition to its current 15-minute infusion regimen. Protonix I.V. is indicated for short-term treatment (7 to 10 days) in patients having gastroesophageal reflux disease with a history of erosive esophagitis. It is an alternative to oral therapy for patients who are unable to continue taking Protonix Delayed-Release Tablets. Protonix is the first and only proton pump inhibitor in the United States to be offered in both oral and IV formulations. Hospital personnel will be able to administer treatment with Protonix I.V. more quickly as a result of the decrease in both preparation time and infusion time. For more information, visit www.wyeth.com, or call 800-395-9938.
While many states across our nation are engaged in political battles over the recreational use of marijuana, researchers have been busy studying the medical benefits of cannabidiol.
News from the year's biggest meetings
Clinical features with downloadable PDFs